CytoDyn Inc.

Stocks

Market Closed - OTC Markets 15:59:35 2026-10-23 EDT			5-day change	1st Jan Change
0.2600 ^USD	+8.38%		+13.91%	-7.14%

10-19	CytoDyn Inc. - Special Call
10-19	CytoDyn Inc. Announces CEO Changes	CI

Published on 10/19/2026 at 05:08 pm EDT - Modified on 10/19/2026 at 07:35 pm EDT

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Greetings, and welcome to today's CytoDyn Investment Community Webcast. My name is Ignacio Guerrero-Ros, and I will serve as your moderator today.

This article is reserved for our subscribers.

Subcribe
to read the article

Unlimited browsing across the entire site

Access to all news and data

US, Europe, and Asia portfolios

Ad-free reading

Pro Tools : expert screeners, historical financials, PDF reports, investment themes, and earnings transcripts

10-19	CytoDyn Inc. - Special Call
10-19	CytoDyn Inc. Announces CEO Changes	CI
10-14	CytoDyn Inc. Reports Earnings Results for the First Quarter Ended August 31, 2026	CI
08-31	CytoDyn Inc. Reports Earnings Results for the Full Year Ended May 31, 2026	CI
08-30	CytoDyn Inc. Auditor Raises 'Going Concern' Doubt	CI
08-27	CytoDyn Inc. announced that it has received $16.50231 million in funding	CI
06-30	CytoDyn Inc. announced that it expects to receive $16.50231 million in funding	CI
06-11	CytoDyn Doses First Patient in Phase 2A Study Evaluating Leronlimab in Alzheimer?s Disease	CI
06-04	Natera and CytoDyn Announces Strategic Collaboration to Advance ctDNA-Guided Development and Molecular Response Analysis in Metastatic Colorectal Cancer	CI
05-01	CytoDyn Inc. - Special Call
04-27	CytoDyn Inc Announces First Patient Dosed in Expanded Access Program for Leronlimab in Triple-Negative Breast Cancer	CI
04-22	CytoDyn Inc Presents New Leronlimab Data in Metastatic Colorectal Cancer	CI
04-21	CytoDyn Inc. Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study	CI
04-20	CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026	CI
04-08	CytoDyn Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended February 28, 2026	CI

Duration

Period

Sector